Risk of Primary Liver Cancer Associated with Gallstones and Cholecystectomy: A Meta-Analysis

Yanqiong Liu, Yu He, Taijie Li, Li Xie, Jian Wang, Xue Qin, Shan Li*

Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China

Abstract

**Background:** Recent epidemiological evidence points to an association between gallstones or cholecystectomy and the incidence risk of liver cancer, but the results are inconsistent. We present a meta-analysis of observational studies to explore this association.

**Methods:** We identified studies by a literature search of PubMed, EMBASE, Cochrane Central Register of Controlled Trials, and relevant conference proceedings up to March 2014. A random-effects model was used to generate pooled multivariable adjusted odds ratios (ORs) and 95% confidence intervals (CIs). Between-study heterogeneity was assessed using Cochran’s Q statistic and the I².

**Results:** Fifteen studies (five case-control and 10 cohort studies) were included in this analysis. There were 4,487,662 subjects in total, 17,945 diagnoses of liver cancer, 328,420 exposed to gallstones, and 884,507 exposed to cholecystectomy. Pooled results indicated a significant increased risk of liver cancer in patients with a history of gallstones (OR = 2.54; 95% CI, 1.71–3.79; n = 11 studies), as well as cholecystectomy (OR = 1.62; 95% CI, 1.29–2.02; n = 12 studies), but there was considerable heterogeneity among these studies. The effects estimates did not vary markedly when stratified by gender, study design, study region, and study quality. The multivariate meta-regression analysis suggested that study region and study quality appeared to explain the heterogeneity observed in the cholecystectomy analysis.

**Conclusions:** Our results suggest that individuals with a history of gallstones and cholecystectomy may have an increased risk of liver cancer.

Introduction

Primary liver cancer mainly includes hepatocellular carcinoma (HCC), which originates in liver cells, and intrahepatic cholangiocarcinoma (ICC), which arises from the intrahepatic bile duct [1]. The worldwide burden of primary liver cancer for 2012 was estimated at 782,000 new cancer cases [2]. It ranks as the fifth most common incident cancer in men and the ninth in women [2].

Owing to its poor prognosis, it is the second commonest cause of death from cancer worldwide [2]. The above data highlight the importance of a better understanding of risk factors related to liver cancer development. However, the etiology of this disease remains largely elusive, apart from known relationships with hepatitis B or C virus infection, alcohol, aflatoxins, liver cirrhosis, and diabetes [3,4].

It has been hypothesized that gallstones (i.e., cholelithiasis) and cholecystectomy are associated with an increased risk of several cancers, especially the risk of rectal cancer [5], pancreatic cancer [6], and colorectal cancer [7,8]. Gallstones are known to induce biliary inflammation, and cholecystectomy is typically followed by dilation of the common bile ducts and elevated bile duct pressure, which also results in chronic inflammation [9]. The link between chronic inflammation and cancer is well established [10]. It has also been proposed that gallstones and cholecystectomy result in the accumulation of bile and secondary bile acids, in particular, deoxycholic acid [11–15], and that bile acids can act as carcinogens [16].

Several epidemiological studies have investigated the association between gallstones, cholecystectomy, and liver cancer [17–31]. However, the existing results are controversial. Most studies have reported a positive relationship between gallstones and liver cancer [17–19,21,22,24,26,27,29,30], but one failed to demonstrate a significant association [23]. With regard to cholecystectomy, several studies suggested a significant increased risk of liver cancer [18,20,24,25,27,28,31], whereas others demonstrated a nonsignificant adverse effect [17,19,21,26,29].

No meta-analysis has previously been published on the relationship between gallstones or cholecystectomy and the incidence risk of liver cancer. The aim of this detailed meta-analysis was to summarize the association between cholecystectomy, gallstones, and the risk of developing liver cancer in...
observational studies. A better understanding of these relationships may highlight the need to consider additional intervention methods in this area.

**Methods**

This study complies with the guidelines of the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) checklist and flow diagram [32] (Checklist S1).

**Data sources and search strategy**

We searched PubMed, EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library for all relevant articles on the risk of liver cancer in patients with history of gallstones or cholecystectomy. The search was performed in each database from time of inception until March 12, 2014 by two independent investigators (Y.L. and S.L.). Medical subject heading terms and keywords used in the search included “cholecyctectomy”, “gallbladder surgery”, “gallstones”, “gallstone”, “cholelithiasis”, “cholecystolithiasis”, “choledocholithiasis” combined with “HCC”, “hepatocellular carcinoma”, “liver cancer”, “liver tumors”, “liver neoplasms”, “hepatic carcinoma”. No language restrictions were imposed. We also reviewed the abstracts submitted to major gastroenterology and hepatology conferences (annual meeting of the American College of Gastroenterology, American Association for the Study of Liver Diseases, Digestive Diseases Week; World Congress of the International Hepato-Pancreato-Biliary Association) between 2009 and 2013. The reference lists in all identified articles were checked for further relevant articles.

**Eligibility criteria and study selection**

Studies considered in this meta-analysis met all the following inclusion criteria: (1) cohort or case-control; (2) focus of the study was a history of gallstones or cholecystectomy; (3) end point was liver cancer incidence; (4) provided multivariate-adjusted relative risks, with corresponding 95% confidence intervals (CIs) for events associated with gallstones or cholecystectomy vs. controls, at least adjusted for three of eight factors (hepatitis B or C virus infection, smoking, alcohol, cirrhosis, diabetes, body mass index, age, gender). Primary exclusion criteria were cross-sectional studies, literature reviews, commentaries, editorials, and case reports. Studies were also excluded where adjusted relative risks and/or CIs had not been provided, or they did not fulfill the inclusion criteria. When there were multiple studies of the same population, only data from the most recent comprehensive report was included. Two authors (Y.L. and Y.H.) independently evaluated articles for further relevant articles. Disagreements regarding eligibility were resolved through discussion and by referencing the original report.

**Data abstraction and quality assessment**

Data were independently abstracted onto a standardized form by two investigators (T.L. and L.X.). Disagreements were resolved through consensus, referring back to the original article. The following data were collected from each study: first author’s name, year of publication, country of the population studied, mean age, study duration, number of patients with gallstones or cholecystectomy studied, number of incident cases of liver cancer, adjustment factors, and multivariable adjusted relative risk estimates and their 95% CIs for these analyses. Odds ratios (ORs) for case-control studies, or standardized incidence rates (SIR) for studies comparing the rates of observed to expected cases. Because the liver cancer incidence is low (<10%) and the estimated effects are small, odds ratios (ORs) can be considered close approximations of risk ratios [33].

The methodological quality of the case-control and cohort studies was initially assessed independently by two authors using the Newcastle-Ottawa scale [34] (X.Q. and S.L.). Disagreements were resolved through discussion with an additional adjudicator (J.W.) who was completely blinded to the study until a consensus was reached. Observational studies were scored across three categories and allocated a maximum of 9 points: selection (up to 4 points), comparability (up to 2 points), and outcome (up to 3 points). The overall study quality was arbitrarily defined as poor (score 0–3), fair (score 4–6), or good (score 7–9).

**Outcomes assessed**

The primary analysis focused on assessing the risk of liver cancer in patients with a history of gallstones, and risk of liver cancer in patients with a history of cholecystectomy. Additionally, based on information available from individual studies, we assessed sex-specific differences in risk estimates.

**Data synthesis and statistical analysis**

We used the random-effects model described by DerSimonian and Laird [33] to calculate summary ORs and 95% CIs. Heterogeneity was first tested by Cochran’s Q test, and a P-value <0.10 was considered suggestive of significant heterogeneity [36]. To explore sources of heterogeneity between the combined studies, we performed subgroup analyses based on study design (case-control vs. cohort), study location (Asian, Europe, and the U.S.), gender, and study quality (good vs. fair, and poor). In addition, a restricted maximum likelihood-based random-effects meta-regression analysis was performed to assess heterogeneity associated with the aforementioned factors [39].

Sensitivity analyses were conducted to assess the robustness of the results by sequential omission of individual studies [40]. Publication bias was assessed graphically using a funnel plot and quantitatively using Egger’s regression asymmetry tests [41]. A 2-tailed P-value less than 0.05 was considered statistically significant for all analyses except for the Cochran’s Q test. All analyses were performed using STATA, version 12.0 (StataCorp, College Station, TX, USA).

**Results**

**Study selection, study characteristics, and quality**

Fig. 1 summarizes the process of study identification, exclusion, and inclusion. Table S1 shows the list of excluded studies from the full text studies review. At least 15 studies fulfilled all inclusion criteria and were included in the meta-analysis [17–31]. Fourteen articles were published in full [17,18,20–31], and one was in abstract form [19]. There were five case control studies [18,22,23,26,27] and 10 cohort studies [17,19–21,24,25,28–31]. Individual study characteristics are outlined in Table 1. Included articles were published in the period 1993–2014. There was a total study population of 4,487,662 individuals, 17,945 of whom had been diagnosed with liver cancer, with 328,420 exposed to gallstones and 884,507 exposed to cholecystectomy. The majority of the studies (n = 8) were conducted in European populations.
Three studies were performed in a North American population [18, 19, 27], and four studies were conducted in an Asian population [17, 20–22]. Thirteen studies were population-based [17–22, 24–27, 29–31], and two were hospital-based [23, 28]. Of the included studies, 11 reported an association between gallstones and the risk of liver cancer [17–19, 21–24, 26, 27, 29, 30]. Twelve studies reported an association between cholecystectomy and the risk of liver cancer [17–21, 24–29, 31].

Table 1 summarizes the methodological quality of all studies, and additional data are given in Table S2. According to the Newcastle-Ottawa scale, most studies were fair (scale of 4–6) to good (scale of 7–9) quality, except the abstract identified from the conference proceedings [19].

Risk of gallstones in the incidence of liver cancer

Eleven studies [17–19, 21–24, 26, 27, 29, 30] reported 7,453 liver cancer events in 328,420 patients with gallstones. The multivariate-adjusted ORs for incident liver cancer with gallstones vs. controls for each study and all studies combined are presented in Fig. 2. The liver cancer incidence was increased in patients with gallstones, with an OR of 2.54 (95% CI, 1.71–3.79) but with considerable heterogeneity ($I^2=97.8\%$; $P<0.001$).

Some studies [17, 22, 24] provided separate estimates of the OR for liver cancer in male and female gallstone patients. An increased risk of liver cancer in patients with gallstones was seen in females (three studies; adjusted OR, 3.29; 95% CI, 1.02–10.62), as well as in males (three studies; adjusted OR, 2.84; 95% CI, 1.44–5.61), with significant evidence of heterogeneity in both subsets (Table 2).

We then conducted further subgroup meta-analysis according to study design, study location, and study quality (Table 2). No substantial differences in the summary ORs were found between case-control and cohort studies, good and fair/poor quality studies, as well as studies conducted in Asia and Western country. All of these analyses were with considerable heterogeneity.

We also conducted a meta-regression analysis to investigate the impact of heterogeneous factors on the OR estimates. The study design, study location, and study quality were chosen as the potential heterogeneous factors. In multivariate meta-regression analysis, none of these factors were significant ($P=0.200$ for study design; $P=0.892$ for study location; $P=0.905$ for study quality). The meta-regression analysis indicated that study design, study location, and study quality might not be major sources contributing to the heterogeneity presented in the overall analyses.

We observed no evidence of overly influential studies in sensitivity analyses based on repeatedly computing the pooled ORs, omitting one study at a time. The pooled ORs ranged from 2.13 (1.68–2.70) when the study by Welzel et al. [27] was excluded, to 2.75 (1.81–4.16) when the study by Tavani et al. [23] was excluded.

In the publication bias assessment, the inverted funnel plot appeared to be symmetric (Fig. 3A). The $P$ value for the Egger test was 0.847, suggesting a very low probability of publication bias.

Risk of cholecystectomy in the incidence of liver cancer

Twelve eligible studies [17–21, 24–29, 31] were included in the analysis of the potential role of cholecystectomy in the risk of liver cancer. These included 884,507 patients with a history of cholecystectomy and 3,687 liver cancer outcome events. Meta-analysis of these 12 studies showed that compared to individuals without a history of cholecystectomy, those who had their gallbladder removed had a 62% greater risk of liver cancer (OR = 1.62, 95% CI, 1.29–2.02), with considerable heterogeneity among studies; test for heterogeneity ($P<0.001$, $I^2=91.0\%$) (Fig. 4).

Four studies reported sex-specific risk estimates of liver cancer [17, 20, 24, 25]. No difference was observed in the risk of liver cancer between males (OR = 1.70; 95% CI, 1.05–2.75) and females (OR = 1.68; 95% CI, 1.00–2.82) with a history of cholecystectomy. There was considerable heterogeneity observed in both analyses (Table 2).

When stratifying the data into subgroups based on study design, study location and study quality (Table 2), we found a significant association between cholecystectomy and risk of liver cancer.

Figure 1. Flow chart depicts the selection of eligible studies.

doi:10.1371/journal.pone.0109733.g001
Table 1. Characteristics of included studies on the association of gallstones, cholecystectomy and risk of liver cancer.

| Study             | Year | Country | Study design | Setting | Average age, years | Period of observation | Exposure | Number of Exposure | Total LC cases | All subjects Total | Adjustment factors | QS |
|-------------------|------|---------|--------------|---------|--------------------|-----------------------|----------|--------------------|----------------|--------------------|-------------------|----|
| Vogtmann et al. [17] | 2014 | China   | Cohort PB    |         | 54.2               | 2000–2010             | Gallstones | 8161               | 160            | 73209              | 1–12              | 7  |
|                   |      |         |              |         |                    |                       | Cholecystectomy | 3151               |                |                    |                   |    |
| SMHS cohort       | 2014 | China   | Cohort PB    |         | 57.4               | 2002–2010             | Gallstones | 4614               | 252            | 61337              | 1–11              | 7  |
|                   |      |         |              |         |                    |                       | Cholecystectomy | 1684               |                |                    |                   |    |
| Nogueira, et al. [18] | 2014 | US      | Case control PB |         | 76.5               | 1992–2005             | Gallstones | 15097              | 10219          | 1,238,390         | 7, 13              | 6  |
|                   |      |         |              |         |                    |                       | Cholecystectomy | 9109               |                |                    |                   |    |
| Nogueira, et al. [19] | 2013 | US      | Cohort PB    |         | NR                 | NR                    | Gallstones | 30,674             | 414            | 487,207            | 1, 2, 4, 5, 9, 10, 14-16 | 2  |
|                   |      |         |              |         |                    |                       | Cholecystectomy | 25,457             |                |                    |                   |    |
| Kao, et al. [20]  | 2013 | China   | Cohort PB    |         | 66.0               | 1996–2008             | Gallstones | 2590               | 67             | 1,002,590         | 1, 14              | 7  |
|                   |      |         |              |         |                    |                       | Cholecystectomy | 2590               | 67             | 1,002,590         | 1, 14              | 7  |
| Chen, et al. [21] | 2013 | China   | Cohort PB    |         | 55.0               | 2000–2010             | Gallstones | 15545              | 791            | 77,725             | 1, 7, 12, 14, 17-20 | 7  |
|                   |      |         |              |         |                    |                       | Cholecystectomy | 5830               |                |                    |                   |    |
| Chang, et al. [22] | 2013 | China   | Case control PB |       | NR                 | 2004–2008             | Gallstones | 1484               | 2978           | 14890              | 1, 7, 8, 14, 18, 19, 20 | 8  |
|                   |      |         |              |         |                    |                       | Cholecystectomy | 25,457             |                |                    |                   |    |
| Tavani, et al. [23] | 2012 | Italy and Switzerland | Case control HB | | 60                  | 1982–2009             | Gallstones | 206                | 684            | 2640               | 1, 2–5, 14, 21-25 | 6  |
|                   |      |         |              |         |                    |                       | Cholecystectomy | 25,457             |                |                    |                   |    |
| Nordenstedt, et al. [24] | 2012 | Sweden  | Cohort PB    |         | 59.9               | 1965–2008             | Gallstones | 192,960            | 70             | 538,211            | 1, 13, 14          | 6  |
|                   |      |         |              |         |                    |                       | Cholecystectomy | 345,251            |                |                    |                   |    |
| Lagergren, et al. [25] | 2011 | Sweden  | Cohort PB    |         | 52.0               | 1965–2008             | Gallstones | 345,251            | 333            | 345,251            | 1, 13, 14          | 6  |
|                   |      |         |              |         |                    |                       | Cholecystectomy | 345,251            |                |                    |                   |    |
| Welzel, et al. [26] | 2007 | Denmark | Case control PB |       | NR                 | 1978–1991             | Gallstones | 35                 | 764             | 3820               | 1, 14, 21          | 7  |
|                   |      |         |              |         |                    |                       | Cholecystectomy | 25                |                |                    |                   |    |
| Welzel, et al. [27] | 2007 | US      | Case control PB |       | 79.0               | 1993–1999             | Gallstones | 4445               | 535            | 103,317            | 1, 14, 15, 26, 27 | 6  |
|                   |      |         |              |         |                    |                       | Cholecystectomy | 1690              |                |                    |                   |    |
| Goldacre, et al. [28] | 2005 | UK      | Cohort HB    |         | 15–84              | 1963–1999             | Gallstones | 39,254             | 344            | 37,067             | 1, 13, 14, 26     | 6  |
|                   |      |         |              |         |                    |                       | Cholecystectomy | 39,254             |                |                    |                   |    |
| Chow, et al. [29]  | 1999 | Denmark | Cohort PB    |         | 61.0               | 1977–1993             | Gallstones | 177,15             | 82             | 601,76             | 1, 13, 14          | 5  |
|                   |      |         |              |         |                    |                       | Cholecystectomy | 42,461            |                |                    |                   |    |
| Johansen, et al. [30] | 1996 | Denmark | Cohort PB    |         | 60.0               | 1977–1992             | Gallstones | 42,098             | 56             | 42,098             | 1, 13, 14          | 5  |
|                   |      |         |              |         |                    |                       | Cholecystectomy | 62,734             | 96             | 62,734             | 1, 13, 14          | 5  |

Abbreviations: PB, population based; HB, hospital based; LC, liver cancer; CI, confidence interval; QS: quality score; NR, not report.

Adjustment factors: 1 age, 2 BMI, 3 education, 4 smoking status, 5 alcohol consumption, 6 family history of liver cancer, 7 history of diabetes, 8 history of hepatitis/chronic liver disease, 9 physical activity, 10 total energy intake, 11, income, 12 menopausal status, 13 calendar years, 14 gender, 15 race, 16 non-steroidal anti-inflammatory drugs intake, 17 perlipidemia, 18 hepatitis B virus infection, 19 hepatitis C virus infection, 20 cirrhosis, 22, chronic pancreatitis, 23 study center, 24 year of interview, 25 study period, 26 geographic region, 27, state buy-in status.
among cohort studies (OR = 1.47) and studies conducted in Europe (OR = 1.30). On restricting analysis to high-quality studies (≥7 scores), we observed a similar association between cholecystectomy and risk of liver cancer (OR = 1.29; 95% CI, 1.21–1.37). However, a non-significant increased risk of liver cancer in patients with cholecystectomy was observed in case-control studies (OR = 2.23; 95% CI, 0.73–6.79), studies conducted in America (OR = 2.14; 95% CI, 0.78–5.88) and in Asia (OR = 1.76; 95% CI, 0.86–3.57).

We then conducted a meta-regression analysis to investigate the impact of study design, study location, and study quality on the estimated ORs. In multivariate meta-regression analysis, study region and study quality were significant factors (P = 0.039 and P = 0.008, respectively), with these two variables explaining most between-study variability.

In sensitivity analyses, the pooled OR remained significantly increased when studies were excluded one at a time, with the pooled OR ranging from 1.44 (1.22–1.70) when the study by Welzel et al. [26] was excluded, to 1.67 (1.31–2.12) when the study by Chen et al. [21] was excluded.

The shape of the funnel plots for studies on the association between cholecystectomy and liver cancer risk seemed somewhat asymmetrical. However, the P-value of Egger’s regression test (P = 0.581) was more than 0.05, indicating no statistical evidence of publication bias (Fig. 3B).

Discussion

To the best of our knowledge, this is the first comprehensive meta-analysis of observational studies to investigate the risk of liver cancer in gallstone patients and cholecystectomy patients. The results of the present meta-analysis of 15 studies point to significant evidence for an increased risk of liver cancer among gallstone patients as compared to those without gallstones (OR = 2.54). In the current study, cholecystectomy was associated with a 62% excess risk of liver cancer. The association persisted across a broad range of sensitivity analyses. Further, the significant association was observed in both women and men. However, there was considerable heterogeneity among most analyses.

There is a long-standing debate about the risk of cancer in patients who have gallstones and undergo cholecystectomy. Several review studies have discussed the potential risk of gallstones or cholecystectomy in various tumors, such as colorectal [42] and colonic adenomas [43], and in several types of cancer, such as colorectal [5,7,8], pancreatic [6], esophageal, and gastric [44]. In 1993, Giovannucci et al. found a 34% increased risk of colorectal cancer following cholecystectomy based on combined results from 33 case-control studies [8]. In addition, an analysis by Lin et al. of 18 studies found that cholecystectomy was associated with a 23% excess risk of pancreatic cancer [6]. In contrast, other studies found no effect of cholecystectomy on the risk of colorectal adenoma [42], esophageal and gastric cancer [44], rectal cancer [7] and colonic adenoma [43]. However, Chiong et al. reported a statistically significant risk of rectal cancer (OR = 1.33) [5] and colonic adenoma (OR = 2.26) [43] if gallstones were present. To date, several epidemiological studies have investigated the relationship between gallstones, cholecystectomy, and the risk of liver cancer, but no definitive conclusions have been drawn. The results of our comprehensive meta-analysis of 15 studies, which included 4,487,662 participants and 17,945 liver cancer cases, suggest that gallstones and cholecystectomy might be important contributors to the risk of liver cancer. An understanding of the clinicopathological development of liver cancer is essential for effective screening.

The pathophysiology of tumorigenesis associated with gallstones and after cholecystectomy has yet to be elucidated. One potential mechanism may involve chronic inflammation. Gallstones may induce biliary inflammation, and cholecystectomy is typically followed by dilation of the common bile ducts and elevated bile duct pressure [9], both of which might cause chronic inflammation. The link between chronic inflammation and cancer is well established. In the microenvironment, chronic inflammation can stimulate the release of cytokines, chemokines, growth factors, reactive oxygen species, and reactive nitrogen intermediates, all of which are important constituents of the local environment of tumors [10]. Inflammatory responses also play decisive roles in the cancer development, including initiation, promotion, invasion,
and metastasis [45]. Conversely, tumor-related inflammation contributes to further production of reactive oxygen species, reactive nitrogen intermediates, and cytokines [10]. Another hypothesis for the pathophysiology of tumorigenesis associated with gallstones is that removal of the gallbladder results in the accumulation of bile, and secondary bile acids, in particular deoxycholic acid [11–13], with the bile acids acting as carcinogens.

Table 2. Subgroup analysis of odds ratios for the association between gallstones, cholecystectomy and the risk of liver cancer.

| Study characteristics | No. of studies | Odds ratios (95% CI) | $P_{OR}$ value | Heterogeneity |
|-----------------------|----------------|----------------------|----------------|--------------|
|                       |                | $F$ (%)              | $P$ value      |              |
| Gallstones            | 11             | 2.54 (1.71, 3.79)    | <0.001         | 97.8         |
|                       |                | $F$ (%)              | $P$ value      |              |
| Study Design          |                | 98.8                 | <0.001         |              |
| Case-control studies  | 5              | 3.66 (1.75, 7.64)    | 0.001          | 98.8         | <0.001       |
| Cohort studies        | 6              | 1.90 (1.60, 2.25)    | <0.001         | 63.8         | 0.017        |
| Study Location        |                |                      |                |              |
| Studies in America    | 3              | 3.86 (1.15, 12.91)   | 0.029          | 99.4         | <0.001       |
| Studies in Europe     | 5              | 2.02 (1.42, 2.86)    | <0.001         | 81.9         | <0.001       |
| Studies in Asia       | 3              | 2.31 (1.19, 4.50)    | 0.013          | 97.4         | <0.001       |
| studies quality       |                |                      |                |              |
| Good (≥7 scores)      | 4              | 2.58 (1.44, 4.62)    | 0.001          | 96.1         | <0.001       |
| Fair and poor (<7 scores) | 7        | 2.51 (1.37, 4.60)    | 0.003          | 98.4         | <0.001       |
| Gender                |                |                      |                |              |
| Males                 | 3              | 2.84 (1.44, 5.61)    | 0.003          | 93.8         | <0.001       |
| Females               | 3              | 3.29 (1.02, 10.62)   | 0.046          | 97.9         | <0.001       |
| Cholecystectomy       | 12             | 1.62 (1.29, 2.02)    | <0.001         | 91.0         | <0.001       |
| Study Design          |                |                      |                |              |
| Case-control studies  | 3              | 2.23 (0.73, 6.79)    | 0.159          | 97.0         | <0.001       |
| Cohort studies        | 9              | 1.47 (1.19, 1.81)    | <0.001         | 85.0         | <0.001       |
| Study Location        |                |                      |                |              |
| Studies in America    | 3              | 2.14 (0.78, 5.88)    | 0.140          | 97.0         | <0.001       |
| Studies in Europe     | 6              | 1.30 (1.20, 1.41)    | <0.001         | 0.0          | 0.794        |
| Studies in Asia       | 3              | 1.76 (0.86, 3.57)    | 0.120          | 94.2         | <0.001       |
| studies quality       |                |                      |                |              |
| Good (≥7 scores)      | 4              | 1.29 (1.21, 1.37)    | 0.019          | 95.4         | <0.001       |
| Fair and poor (<7 scores) | 8        | 2.32 (1.15, 4.69)    | <0.001         | 0.0          | 0.911        |
| Gender                |                |                      |                |              |
| Males                 | 4              | 1.70 (1.05, 2.75)    | 0.031          | 90.4         | <0.001       |
| Females               | 4              | 1.68 (1.00, 2.82)    | 0.049          | 91.9         | <0.001       |

doi:10.1371/journal.pone.0109733.t002

Figure 3. Funnel plot analysis to detect publication bias. A Funnel plot for studies evaluating the association between gallstones and liver cancer risk; B Funnel plot for studies evaluating the association between cholecystectomy and liver cancer risk.

doi:10.1371/journal.pone.0109733.g003
Gallstones are thought to block the flow of bile through the cystic duct.

Heterogeneity is a potential problem when interpreting the results of all meta-analyses, and finding the sources of heterogeneity is one of the most important goals of any meta-analysis [46]. In our meta-analysis, considerable heterogeneity was observed in most of the analyses. To investigate the sources of heterogeneity, we performed subgroup and meta-regression analyses. In the gallstone studies, despite stratifying the data into subgroups based on study design, study location, study quality, and gender, significant heterogeneity was still detected. The multivariate meta-regression analysis also suggested that none of these variables could explain the heterogeneity observed in the overall analysis.

With respect to cholecystectomy, subgroup analyses by study design, study location, and study quality indicated that heterogeneity still existed in the case-control studies, cohort studies, U.S. studies, Asian studies, and high-quality score studies. There was little evidence of heterogeneity in the subgroup analyses of studies in Europe ($P = 0.794$, $I^2 = 0.0\%$) and low-quality studies ($P = 0.911$, $I^2 = 0.0\%$). To further investigate the heterogeneity, multivariate meta-regression analyses were performed. Meta-regression analysis of the data showed that the study region and study quality might substantially influence the initial heterogeneity. When these two parameters were considered together, the results indicated that the U.S. and Asian studies might be a major source of the heterogeneity in the cholecystectomy data.

The presence of heterogeneity in study design, population characteristics, sample size, information collection methods (e.g., questionnaires or medical records), definition of exposure, assessment of outcome, period of observation, and duration of study follow-up is not surprising. For example, in the 15 studies included in the present meta-analysis, the period of observation was from 1963 to 2010. The older studies [23,25,28–30] did not seem to be adequately powered to detect a significant difference in liver cancer incidence following gallstones and cholecystectomy, with a low risk ratio reported in these studies. The period of observation of these studies was up to 36 years (from 1963 to 1999). As the most important etiology of primary liver cancer is hepatitis B or C virus infection, we suspect that the low risk ratio may be due to the exclusion of hepatitis C virus infection in the older studies. We suspect that the low risk ratio may be due to without exclusion of hepatitis C virus infection. Thus, pooled effect estimates based on heterogeneous data should be interpreted with caution.

Our study has several strengths. First, our meta-analysis included 15 studies, involving 4,487,662 participants and 17,945 liver cancer cases. The large sample size afforded increased statistical power. We were also able to carry out multiple subgroup analyses and evaluate heterogeneity and the presence of publication bias. Moreover, the present meta-analysis included an approved quality evaluation system. Thus, it minimized potential bias. Further, the likelihood of important selection or publication bias in our meta-analysis is small.

However, several limitations should be acknowledged when interpreting our findings. First, there was significant evidence of considerable heterogeneity among almost all the analyses, despite stratifying the data into subgroups based on several variables. Second, all studies included in our analysis were observational studies, which have inherent limitations. Therefore, confounding factors and bias might have distorted the results [47]. In particular, in the case-control studies, we cannot rule out the possibility of recall bias. Third, as shown in Table 1, the number and content of the adjusted confounders differed between studies. The established risk factors for liver cancer include hepatitis B/C virus infection, contamination of foodstuff with aflatoxins, smoking, alcohol, liver cirrhosis, and diabetes [3,4]. Most studies [17,19–31] adjusted for age and gender using multivariate statistical models. Some studies [17,19,21–23] adjusted for smoking, alcohol, liver cirrhosis, diabetes, and family history of liver cancer. Only a few studies [21,22] adjusted for hepatitis B or C virus infection. The effects of gallstones and cholecystectomy on the risk of liver cancer may be overestimated if other risk factors for liver cancer are imprecisely measured. However, researchers do not always consider the same factors to be potential confounders. It is also almost impossible to obtain and analyze effects estimates extracted from homogeneous models. We believe that selecting the most multivariable-adjusted
Thus, publication bias remains one possible alternative explanation for our positive finding of an association between gallstones and cholecystectomy and an increased risk of liver cancer.

In conclusion, although this meta-analysis has some limitations, particularly the heterogeneity of the studies, the results suggest that a history of gallstones and cholecystectomy is associated with an increased risk of liver cancer. This issue would probably be best addressed using well-designed prospective studies with adequate exposure measurements, accurate case definition, and careful adjustment for major confounders.

References

1. Ahmed I, Lobo DN (2009) Malignant tumours of the liver. Surgery 27: 30–37.
2. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, et al (2013) GLOBOCAN 2012 v1.0. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer. Available: http://globocan.iarc.fr. Accessed 24 April 2015.
3. Chung SC, Lee Vecchia C, Boffetta P (2009) Liver cancer: Descriptive epidemiology and risk factors other than HBV and HCV infection. Cancer Letters 286: 9–14.
4. Ha NB, Ha NB, Ahmed A, Aysub W, Daugherty TJ, et al (2012) Risk factors for hepatocellular carcinoma in patients with chronic liver disease: a case-control study. Cancer Causes Control 23: 453–462.
5. Chiong C, Cox MR, Edick GD (2012) Gallstone disease is associated with rectal cancer: a meta-analysis. Scandinavian Journal of Gastroenterology 47: 553–564.
6. Lin G, Zeng Z, Wang X, Wu Z, Wang J, et al (2012) Cholecystectomy and risk of pancreatic cancer: a meta-analysis of observational studies. Cancer Causes Control 23: 39–49.
7. Reid FD, Mercer PM, Harrison M, Bates T (1996) Cholecystectomy as a risk factor for colorectal cancer: a meta-analysis. Scand J Gastroenterol 31: 160–169.
8. Giovannucci E, Colditz GA, Stampfer MJ (1993) A meta-analysis of cholecystectomy and risk of colorectal cancer. Gastroenterology 105: 130–141.
9. Chung SC, Leung JW, Li AK (1996) Bile duct size after cholecystectomy: an endoscopic retrograde cholangiopancreatographic study. Br J Surg 77: 534–535.
10. Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 453: 436–444.
11. Jemal SS, Mohandas S, Almond LM (2010) Postcholecystectomy syndrome (PCS). Int J Surg 8: 15–17.
12. Malagelada JR, Go VL, Summerskill WH, Gamble WS (1973) Bile acid secretion and biliary bile acid composition altered by cholecystectomy. Am J Dig Dis 18: 455–459.
13. Pomer VE, Heaton KW (1973) The effect of cholecystectomy on bile salt metabolism. Gut 14: 733–762.
14. Pomer VE, Heaton KW (1973) Bile salt metabolism in patients with gallstones in functioning gallbladders. Gut 14: 895–890.
15. Berr F, Pratschke E, Fischer S, Paumgartner G (1992) Disorders of bile acid metabolism in cholecystolithiasis. J Clin Invest 90: 859–868.
16. Perez MJ, Briz O (2009) Bile-acid-induced cell injury and protection. World J Gastroenterol 15: 1677–1689.
17. Vogtmann E, Shu XO, Li HL, Chow WH, Yang G, et al (2014) Cholecystectomy and the risk of liver cancer: results from cohort studies of 134 546 Chinese men and women. J Epidemiol Community Health.
18. Nogueira L, Freedman ND, Engels EA, Warren JL, Castro F, et al (2014) Gallstones, cholecystectomy, and risk of digestive system cancers. Am J Epidemiol 179: 731–739.
19. Nogueira L, Cross A, Freedman N, Lai G, Castro F, et al (2013) Gallstones, cholecystectomy, and risk of digestive system cancers. Cancer Research 73: 1221–1228.
20. Kao WY, Hwang CY, Su CW, Chang YT, Luo JC, et al (2013) Risk of hepatobiliary cancer after cholecystectomy: a nationwide cohort study. J Gastroenterol Hepatol 28: 1345–1353.
21. Chen YK, Yeh JH, Lin CL, Peng CL, Sung FC, et al (2013) Cancer risk in patients with cholecystolithiasis and after cholecystectomy: a nationwide cohort study. J Gastroenterol Hepatol 28: 1345–1353.
22. Chang JS, Tsai CR, Chen LT (2013) Medical risk factors associated with cholangiocarcinoma in Taiwan: a population-based case-control study. PLoS One 8: e69981.
23. Tavani A, Rosato V, Di Palma F, Bosetti C, Talaman A, et al (2012) History of cholecystitis and cancer risk in a network of case-control studies. Ann Oncol 23: 2173–2176.
24. Nordenström H, Mattsson F, El-Serag H, Lagergren J (2012) Gallstones and cholecystectomy in relation to risk of intra- and extrahepatic cholangiocarcinoma. British Journal of Cancer 106: 1011–1015.
25. Lagergren J, Mattsson F, El-Serag H, Nordström H (2011) Increased risk of hepatocellular carcinoma after cholecystectomy. Br J Cancer 105: 154–156.
26. Welzel TM, Mellerkjaer L, Gloria G, Sakoda LC, Huang AW, et al (2007) Risk factors for intrahepatic cholangiocarcinoma in a low-risk population: a nationwide case-control study. Int J Cancer 120: 630–641.
27. Welzel TM, Graubard BI, El-Serag HB, Shaib YH, Huang AW, et al (2007) Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol 5: 1221–1226.
28. Goldacre MJ, Abiseged JD, Seagroatt V, Yates D (2005) Cancer after cholecystectomy: record-linkage cohort study. Br J Cancer 92: 1307–1309.
29. Chow WH, Johansen C, Gridley G, Mellerkjaer L, Olsen JH, et al (1999) Gallstones, cholecystectomy and risk of cancers of the liver, biliary tract and pancreas. Br J Cancer 79: 640–644.
30. Johansen C, Chow WH, Jorgensen T, Mellerkjaer L, Englund G, et al (1996) Risk of colorectal cancer and other cancers in patients with gall stones. Gut 39: 493–494.
31. Ekbom A, Hux CH, Yuen J, Trichopoulos D, McLaughlin JK, et al (1993) Risk of extrahepatic biliary duct cancer after cholecystectomy. Lancet 342: 1262–1265.
32. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339: b2535.
33. Zhang J, Yu KF (1998) What’s the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA 280: 1690–1691.
34. Wells GA, Shea B, O’Connell D, Peterson J, Welch V, et al (2008) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute.
35. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177–188.
36. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557–560.
37. Higgins JP and Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539–1558.
38. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, et al (2011) GRADE guidelines: 7. Rating the quality of evidence— inconsistency. J Clin Epidemiol 64: 1294–1302.
39. Berkley CS, Hoaglin DC, Mosteller F, Colditz GA (1995) A random-effects regression model for meta-analysis. Stat Med 14: 395–411.
40. Copas J, Shi JQ (2000) Meta-analysis, funnel plots and sensitivity analysis. Biostatistics 1: 247–262.
41. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629–634.

Supporting Information

Table S1 References for studies excluded from the full text studies review. (DOC)

Table S2 Newcastle–Ottawa scale for assessment of study quality. A case control studies; B cohort studies. (DOC)

Checklist S1 PRISMA check list. (DOC)

Acknowledgments

We thank Scribd.com for its linguistic assistance during the preparation of this manuscript.

Author Contributions

Conceived and designed the experiments: YL YH XQ SL. Performed the experiments: YL LX TL. Analyzed the data: YL YH. Contributed reagents/materials/analysis tools: JW. Contributed to the writing of the manuscript: YL YH.
42. Zhao C, Ge Z, Wang Y, Qian J (2012) Meta-analysis of observational studies on cholecystectomy and the risk of colorectal adenoma. Eur J Gastroenterol Hepatol 24: 375–381.
43. Chiong C, Cox MR, Edick GD (2012) Gallstones are associated with colonic adenoma: a meta-analysis. World J Surg 36: 2202–2209.
44. Ge Z, Zhao C, Wang Y, Qian J (2012) Cholecystectomy and the risk of esophageal and gastric cancer. Saudi Med J 33: 1073–1079.
45. Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140: 883–899.
46. Ioannidis JP, Patsopoulos NA, Evangelou E (2007) Uncertainty in heterogeneity estimates in meta-analyses. BMJ 335: 914–916.
47. Grimes DA, Schulz KF (2002) Bias and causal associations in observational research. Lancet 359: 248–252.